Correlation Between OCT and Mf-ERG Findings With BCVA in Patients With Macular Dystrophy

Correlation Between Optical Coherence Tomography and Multifocal Electroretinogram Findings With Visual Acuity in Patients With Macular Dystrophy

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07171541

Enrollment

Registered

2025-09-12

Start date

2025-09-20

Completion date

2025-12-20

Last updated

2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Dystrophy

Brief summary

Correlation between optical coherence tomography and multifocal electroretinogram findings with visual acuity in patients with macular dystrophy.

Detailed description

Macular dystrophies cause progressive central vision loss, but the relationship between structural retinal changes (OCT) and functional deficits (mf-ERG) with visual outcomes remains poorly understood. Current clinical assessment relies primarily on visual acuity, which inadequately reflects retinal damage or predicts disease progression. This knowledge gap limits prognostic accuracy and optimal patient management. Recent advances in OCT and mf-ERG technology provide an opportunity to establish robust structure-function correlations. Understanding these relationships will enhance patient care through improved prognosis, standardized monitoring protocols, and better clinical trial outcome measures for macular dystrophy patients.

Interventions

DIAGNOSTIC_TESTOCT ,mFERG,VA test

retinal photography by OCT, VA measurement, and mfERG test

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All patients diagnosed with macular dystrophy in Tiba Eye Centre, Egypt, Assiut, during the period of the study

Exclusion criteria

* The patients diagnosed with macular dystrophy refuse to contribute to the study.

Design outcomes

Primary

Measure	Time frame	Description
BCVA (best corrected visual acuity)	Day 1/month 3	BCVA was recorded in 30 eyes of 30 patients with macular dystrophy.
CMT (central macular thickness) μm Central macular thickness measurement using optical coherence tomography	Day1/month 3	CMT (central macular thickness) in μm in 30 eyes of 30 patients with macular dystrophy Central macular thickness measurement using optical coherence tomography.
mf-ERG amplituide nV/deg2	Day 1/month 6	mf-ERG amplitude nV/deg² in 30 eyes of 30 patients with macular dystrophy multifocal electroretinogram amplitude measurement using the mf-ERG machine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026